'Tis the season for dupilumab?
- PMID: 38569752
- DOI: 10.1016/j.anai.2024.01.020
'Tis the season for dupilumab?
Conflict of interest statement
Disclosures Dr Anderson has served as a consultant for Regeneron, Sanofi, and Genentech and has received program development support from the COPIC Medical Foundation and Colorado Medicaid Supplement Funding Program. Dr McCulloch has no disclosures.
Comment on
-
Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma.Ann Allergy Asthma Immunol. 2024 Apr;132(4):477-484.e4. doi: 10.1016/j.anai.2023.11.021. Epub 2023 Nov 25. Ann Allergy Asthma Immunol. 2024. PMID: 38013139
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources